📊 CLNN Key Takeaways
Is Clene Inc. (CLNN) a Good Investment?
Clene Inc. exhibits severe financial distress with negative stockholders' equity of -$18.8M, indicating technical balance sheet insolvency. The company generates negligible revenue ($15.0K) while burning approximately $4.5M annually in operating cash flows, providing less than 1.5 years of runway on current cash reserves. Despite modest YoY loss improvement, the fundamental absence of commercial revenue and heavy leverage relative to assets presents extreme risk.
Clene Inc.'s fundamentals are extremely weak, with minimal revenue, deeply negative operating and net margins, and free cash flow losses that are vastly larger than sales. The balance sheet is stressed by negative equity, sub-1.0 liquidity, and meaningful long-term debt, while the modest year-over-year improvement in net loss does not offset the company's severe cash burn and limited commercial traction.
Clene Inc. Key Strengths (CLNN)
- Cash position of $5.9M provides near-term liquidity buffer
- Net loss improved 33.6% YoY suggesting cost discipline efforts
- Current and Quick ratios above 1.9x indicate acceptable short-term solvency
- Net loss improved year over year, indicating some expense discipline versus the prior period
- The company still holds cash on hand, providing limited near-term operating flexibility
- Capital expenditure needs are currently low, which reduces additional cash demands from fixed investment
CLNN Stock Risks: Clene Inc. Investment Risks
- Negative stockholders' equity of -$18.8M represents technical insolvency and complete equity value destruction
- Operating cash burn of -$4.5M annually with only 1.3 years of cash runway remaining
- Total liabilities ($40.5M) nearly double total assets ($21.7M) creating severe leverage pressure
- Revenue collapse of -41.5% YoY with near-zero revenue generation capability
- Revenue is extremely small and declined 41.5% year over year, signaling weak growth quality and limited commercialization
- Negative stockholders' equity and a current ratio of 0.83x indicate financial distress and constrained balance-sheet flexibility
- Operating cash flow and free cash flow are deeply negative, creating ongoing funding risk and potential reliance on external capital
Key Metrics to Watch
- Monthly cash burn rate and projected runway to funding events
- Revenue trajectory and evidence of commercial traction
- Debt covenant compliance and refinancing requirements
- Quarterly cash burn relative to cash balance
- Revenue growth and operating loss trend
Clene Inc. (CLNN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Clene Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
CLNN Profit Margin, ROE & Profitability Analysis
CLNN vs Healthcare Sector: How Clene Inc. Compares
How Clene Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Clene Inc. Stock Overvalued? CLNN Valuation Analysis 2026
Based on fundamental analysis, Clene Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Clene Inc. Balance Sheet: CLNN Debt, Cash & Liquidity
CLNN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Clene Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-5.67 indicates the company is currently unprofitable.
CLNN Revenue Growth, EPS Growth & YoY Performance
CLNN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $15.0K | -$751.0K | $-0.09 |
| Q3 2025 | $15.0K | -$751.0K | $-0.85 |
| Q2 2025 | $27.0K | -$751.0K | $-0.78 |
| Q1 2025 | $73.0K | -$751.0K | $-0.09 |
| Q3 2024 | $87.0K | -$2.4M | $-0.38 |
| Q2 2024 | $91.0K | -$6.8M | $-1.06 |
| Q1 2024 | $73.0K | -$11.1M | $-0.09 |
| Q3 2023 | $108.0K | -$2.4M | $-0.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Clene Inc. Dividends, Buybacks & Capital Allocation
CLNN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Clene Inc. (CIK: 0001822791)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CLNN
What is the AI rating for CLNN?
Clene Inc. (CLNN) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CLNN's key strengths?
Claude: Cash position of $5.9M provides near-term liquidity buffer. Net loss improved 33.6% YoY suggesting cost discipline efforts. ChatGPT: Net loss improved year over year, indicating some expense discipline versus the prior period. The company still holds cash on hand, providing limited near-term operating flexibility.
What are the risks of investing in CLNN?
Claude: Negative stockholders' equity of -$18.8M represents technical insolvency and complete equity value destruction. Operating cash burn of -$4.5M annually with only 1.3 years of cash runway remaining. ChatGPT: Revenue is extremely small and declined 41.5% year over year, signaling weak growth quality and limited commercialization. Negative stockholders' equity and a current ratio of 0.83x indicate financial distress and constrained balance-sheet flexibility.
What is CLNN's revenue and growth?
Clene Inc. reported revenue of $15.0K.
Does CLNN pay dividends?
Clene Inc. does not currently pay dividends.
Where can I find CLNN SEC filings?
Official SEC filings for Clene Inc. (CIK: 0001822791) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CLNN's EPS?
Clene Inc. has a diluted EPS of $-0.46.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CLNN's fundamental grade?
Based on our AI fundamental analysis in June 2026, Clene Inc. has a D grade with 94% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CLNN stock overvalued or undervalued?
Valuation metrics for CLNN: ROE of N/A (sector avg: 15%), net margin of -53,940.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CLNN's AI grade for 2026?
Our dual AI analysis gives Clene Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CLNN's free cash flow?
Clene Inc.'s operating cash flow is $-4.5M, with capital expenditures of $39.0K. FCF margin is -30,446.7%.
How does CLNN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -53,940.0% (avg: 12%), ROE N/A (avg: 15%), current ratio 1.94 (avg: 2).